Amyotrophic Lateral Sclerosis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of amyotrophic lateral sclerosis (ALS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of ALS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for other countries.
Clarivate Epidemiology’s ALS forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following ALS subpopulations:
- Diagnosed prevalent cases by comorbidity status.
- Diagnosed prevalent cases by subtype status.
Note: Coverage may vary by country.
Table of contents
- Amyotrophic Lateral Sclerosis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Prevalence of Definite Amyotrophic Lateral Sclerosis per 100,000 Among Adults in 2020 and 2040
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Definite Amyotrophic Lateral Sclerosis Over the Next 20 Years
- Key Findings
- Epidemiology Data
- Methods
- Lifetime DALYs Gained
- Diagnosed Incident Cases (Definite)
- Diagnosed Incident Cases (Definite + Probable)
- Diagnosed Prevalent Cases (Definite)
- Diagnosed Prevalent Cases (Definite + Probable)
- Subtype Cases
- Diagnosed Prevalent Cases by Comorbidity
- Drug-Treated Prevalent Cases of Amyotrophic Lateral Sclerosis
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Amyotrophic Lateral Sclerosis
- Studies Excluded from the Analysis of Amyotrophic Lateral Sclerosis
- Risk/Protective Factors
- Risk/Protective Factors for Amyotrophic Lateral Sclerosis
- Bibliography
- Glossary
- Literature Review
- Introduction
Julie Davis, M.P.H., Senior Epidemiologist, Epidemiology. Before joining Clarivate, Ms. Davis was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with zoonotic disease transmission in Ethiopia and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and disease risk assessments. Ms. Davis holds a master’s degree in global health epidemiology and disease control from George Washington University and a B.S. in health sciences from James Madison University.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.